Get the Stockscreener App
25.71
2.84%
0.71
After Hours:
26.99
1.28
+4.98%
Tourmaline Bio Inc stock is traded at $25.71, with a volume of 376.47K.
It is up +2.84% in the last 24 hours and up +52.58% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$25.00
Open:
$24.89
24h Volume:
376.47K
Relative Volume:
1.56
Market Cap:
$657.71M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
-166.19
EPS:
-0.1547
Net Cash Flow:
$-19.23M
1W Performance:
+11.78%
1M Performance:
+52.58%
6M Performance:
+12.27%
1Y Performance:
+0.00%
1-Day Range:
$24.52
$26.00
1-Week Range:
$22.20
$26.00
52-Week Range:
$12.06
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - The Globe and Mail
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Acquired by Blue Owl Capital Holdings LP - MarketBeat
Rhumbline Advisers Acquires 33,123 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Trading Up 2.5% - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Trading 2.5% Higher - Defense World
HighVista Strategies LLC Purchases 30,345 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Down 5% - MarketBeat
Keeping an Eye on Tourmaline Bio Inc (TRML) After Insider Trading Activity - Knox Daily
HighVista Strategies LLC Acquires 30,345 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Was anything positive for Tourmaline Bio Inc (TRML) stock last session? - US Post News
Monitoring Red Robin Gourmet Burgers Inc (RRGB) after recent insider movements - Knox Daily
An Analysis of Alkami Technology Inc (ALKT)’s Potential Price Growth - Knox Daily
Bank of New York Mellon Corp Takes $909,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Bank of New York Mellon Corp Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Quest Partners LLC Increases Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
BSR Real Estate Investment Trust (OTCMKTS:BSRTF) Short Interest Update - Defense World
Touax: share price declines after lackluster half-year results - Marketscreener.com
Tourmaline Bio (NASDAQ:TRML) Trading 3.9% Higher - MarketBeat
Tourmaline Oil Corp. stock falls Wednesday, underperforms market - MarketWatch
Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World
Commonwealth Equity Services LLC Has $979,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
TransMedics Stock: Take Profits While The Valuation Is Sky High (NASDAQ:TMDX) - Seeking Alpha
Treace Medical Concepts CEO buys $265k worth of company stock - Investing.com India
Tourmaline Oil Corp. stock rises Tuesday, outperforms market - MarketWatch
Tourmaline Oil (TSE:TOU) Given New C$67.00 Price Target at Jefferies Financial Group - Defense World
Zacks.com featured highlights include TransMedics, Iamgold, Graham and GIII Apparel - Yahoo Finance
Tourmaline Oil Corp. stock falls Monday, underperforms market - MarketWatch
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results - Precision Medicine Online
TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors - OncLive
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.80 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Analysts - Defense World
Tenon Medical stock soars to 52-week high of $13.93 amid robust gains - Investing.com
Tourmaline Bio amends bylaws, updates proxy rules - Investing.com
The Attractiveness of Investing In Tourmaline Bio Inc (TRML) is Growing - Knox Daily
Tourmaline Bio amends bylaws, updates proxy rules - Investing.com India
Tourmaline Bio Showcases Promising Candidate in Updated Presentation - TipRanks
Tourmaline Oil Corp. (TSE:TOU) Senior Officer Mike Rose Purchases 2,500 Shares of Stock - Defense World
Tourmaline Bio to Present at Upcoming Investor Conferences - StockTitan
Investing in Tourmaline Bio Inc (TRML) Is Getting More Attractive - Knox Daily
A Tale of Resilience: Tourmaline Bio Inc Amid Stock Market Turbulence - The InvestChronicle
Tourmaline Bio CEO buys $26.4k of company stock - Investing.com India
Tourmaline Bio CEO buys $26.4k of company stock - Investing.com
Tourmaline Bio CEO buys $26.4k of company stock By Investing.com - Investing.com UK
Tourmaline Bio (NASDAQ:TRML) versus Turnstone Biologics (NASDAQ:TSBX) Head-To-Head Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) CEO Sandeep Chidambar Kulkarni Purchases 5,221 Shares of Stock - Defense World
INFINI RES FPO [I88] (ASX:I88) Insider Charles Armstrong Acquires 150,000 Shares of Stock - Defense World
SG Americas Securities LLC Purchases Shares of 33,666 Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
4,526 Shares in Innovator Growth-100 Power Buffer ETF – July (BATS:NJUL) Bought by Brookstone Capital Management - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.80 Consensus Target Price from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):